The estimated Net Worth of Padmanabh P. Bhatt is at least $8.98 million dollars as of 20 August 2024. Padmanabh Bhatt owns over 1,250 units of Supernus Pharmaceuticals Inc stock worth over $318,601 and over the last 12 years he sold SUPN stock worth over $7,354,121. In addition, he makes $1,311,590 as Senior Vice President - Intellectual Property et Chief Scientific Officer at Supernus Pharmaceuticals Inc.
Padmanabh has made over 38 trades of the Supernus Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 1,250 units of SUPN stock worth $38,850 on 20 August 2024.
The largest trade he's ever made was selling 67,132 units of Supernus Pharmaceuticals Inc stock on 10 May 2018 worth over $3,565,381. On average, Padmanabh trades about 8,739 units every 78 days since 2012. As of 20 August 2024 he still owns at least 10,251 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Padmanabh Bhatt stock trades at the bottom of the page.
Dr. Padmanabh P. Bhatt Ph.D. serves as Senior Vice President - Intellectual Property, Chief Scientific Officer of the Company. Prior to that, he served as our Vice President of Pharmaceutical Sciences since 2005. From 2003 to 2005, Dr. Bhatt was Vice President of Advanced Drug Delivery at Shire Laboratories Inc. From 2001 to 2003, Dr. Bhatt served as Vice President of Research and Development and Chief Technology Officer at Point Biomedical Corporation. From 1996 to 2001, he served at ALZA Corporation (now a Johnson & Johnson company) in various positions from Product Development Manager to Director of Technical Development. Prior to that time, Dr. Bhatt held positions as Research Specialist and Group Leader of Novel Drug Delivery at Dow Corning Corporation (from 1992 to 1996) and Senior Scientist at Hereon Laboratories (from 1989 to 1992). Dr. Bhatt earned his B.Pharm. and M.Pharm. degrees from the University of Bombay, India. He also holds M.S. and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas.
As the Senior Vice President - Intellectual Property et Chief Scientific Officer of Supernus Pharmaceuticals Inc, the total compensation of Padmanabh Bhatt at Supernus Pharmaceuticals Inc is $1,311,590. There are 3 executives at Supernus Pharmaceuticals Inc getting paid more, with Jack Khattar having the highest compensation of $8,123,130.
Padmanabh Bhatt is 62, he's been the Senior Vice President - Intellectual Property et Chief Scientific Officer of Supernus Pharmaceuticals Inc since 2012. There are 7 older and 8 younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.
Padmanabh's mailing address filed with the SEC is 1550 E Gude Dr, Rockville, MD 20850, USA.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell et Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: